Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Clinical trial NCT05230810 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05230810
Sponsor: Criterium, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Metastatic Breast Cancer

Start date: 2022-08-25
Primary completion: 2026-03-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.